Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BacterOMIC

Financiado

Cerrado

Intelligence for precision therapies against antimicrobial resistance The first...

Intelligence for precision therapies against antimicrobial resistance The first diagnostic panel that probes all the clinically relevant antibiotics at once In the recent years, we have seen a drastic increase in the antibiotic resistance among bacterial pathogens. This is considered as one of the biggest threats to global health in the current era. The reason for that is inappropriat... ver más

31/12/2021

BACTEROMIC

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

BACTEROMIC SPOLKA Z OGRANICZONA ODPOWIEDZIALN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

BACTEROMIC

1.93M€ | Lider

SISTELEC SOLUCIONES DE TELEC...

896.17K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TAILORED-TREATMENT DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND... 8M€ Cerrado

ResisCHIP Rapid chip-based detection of antibiotic resistances 150K€ Cerrado

Nanosynex Ultra fast Antimicrobial Susceptibility Test for diagnosing... 71K€ Cerrado

BADGER calScreener an innovative device for Bacterial Analysis a... 71K€ Cerrado

RAPID Rapid Antimicrobial susceptibility testing and phylogenetic... 150K€ Cerrado

C4L Chips for Life 4M€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2019-10-29
Fecha Fin: 2021-12-31

Líder del proyecto

BACTEROMIC SPOLKA Z OGRANICZONA ODPOWIEDZIALN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In the recent years, we have seen a drastic increase in the antibiotic resistance among bacterial pathogens. This is considered as one of the biggest threats to global health in the current era. The reason for that is inappropriate use of antibiotics - patients are often treated with not optimal antibiotic that need to be changed after few days. Number of resistant microorganisms constantly elevates due to inappropriate use of antibiotics - patients are often treated with inappropriate drugs that need to be changed after few days if bacteria turns to be resistant. The reason for that is that current manual antibiotic resistance tests are time-consuming and laborious, while automatic antimicrobial tests offer analysis of a short lists of antibiotics. BacterOMIC is a response to the growing global threat of antibiotic resistance. We provide the first fully comprehensive rapid Antimicrobial Susceptibility Testing (AST) system to determine already in 4h which from all common antibiotics will be most successful in treating certain bacterial infection. Unlike current methods, our system also allows to investigate antimicrobial effect of not only single antibiotics but also combinations of multiple antibiotics – the future of infection disease treatment. Constantly growing antimicrobial susceptibility testing market was valued at EUR 2.4 billion in 2018 and is expected to reach EUR 3.1 billion by 2022 at the CAGR of 5.1%. With our clear business model we target pharmaceutical and biotechnology companies, contract research organizations, hospitals/private healthcare centers, and diagnostic laboratories. We have a network of partnerships across the EU (PL, FR, ES, CH, DE, and PT) and we are ready for rapid scale-up, with more than 30 million cumulative profit by 2025. We need SME Instrument phase 2 to optimize the design, prepare for mass production, validate the system in clinical trials, and certify it for successful commercialization.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores